Author Archives: admin

Papers on stress-induced stem cells are retracted

By adminJuly 2, 2014Stem Cell Medical Center

Asahi Shimbun/Getty Images

Haruko Obokata, here at a 9 April news conference in Osaka, Japan, was found guilty of misconduct but stands by her claim of having produced stem cells by a novel procedure.

Nature today retracted two controversial papers on stem cells that it published in January1, 2. The retractions agreed to by all of the co-authors come at the end of a whirlwind five months during which various errors were spotted in the papers, attempts to replicate the experiments failed, the lead author was found guilty of misconduct, and the centre where she is employed was threatened with dismantlement. The retraction notice3 includes a handful of problems with the papers that had not been previously considered by institutional investigation teams.

Questions remain over what exactly was the basis for claims that embryonic-like stem cells could be created by exposing bodily cells to stress a technology the authors called stimulus-triggered acquisition of pluripotency, or STAP. But the controversy promises to have lasting impact on science in Japan, global stem-cell research, and the scientific community more broadly including changes in editorial policy at Nature. An Editorial posted today with the retractions notes the need for improvements in publishing procedures: The episode has further highlighted flaws in Natures procedures and in the procedures of institutions that publish with us. (Natures news and comment team is editorially independent of its research editorial team.)

The first of the two papers1 described a method of using acid exposure or physical pressure to convert spleen cells from newborn mice into pluripotent cells cells that can become any cell in the body. The second paper2 further impressed stem-cell scientists with data showing that the STAP process created cells that could differentiate into placenta cells, something that other pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells, do not normally do.

But within weeks, duplicated and manipulated images were discovered, focusing attention on the source of data provided by Haruko Obokata, a biochemist at the RIKEN Center for Developmental Biology in Kobe and first author on both papers. Scientists also reported difficulties in replicating the experiments.

A RIKEN investigation team looking into the papers announced on 1 April that Obokata had been found guilty of two counts of scientific misconduct. RIKEN rejected an appeal, and advised her to retract the papers in May. Co-author Teruhiko Wakayama of the University of Yamanishi had been arguing for retraction since March.

Obokata and Charles Vacanti, an anaesthesiologist at the Brigham and Womens Hospital in Boston, Massachusetts, and the senior corresponding author on the first article, both stood by its claims, but later changed their positions after new errors emerged. Obokata gave her consent to the retraction of both papers on 4 June.

The retraction notice published today lists five new errors. The first four note that captions do not describe what is in the corresponding images or figures, without reflecting on how this relates to the experimental data. The fifth, relating to the first paper1, notes that purported STAP cells are of a different genetic background from those supposedly used in the experiments something it calls inexplicable discrepancies.

The notice concludes: These multiple errors impair the credibility of the study as a whole and we are unable to say without doubt whether the STAP-SC [stem cell] phenomenon is real.

Read the original post:
Papers on stress-induced stem cells are retracted

Acid-bath stem cell papers are finally retracted

By adminJuly 2, 2014Uncategorized

The STAP stem cell saga has reached its bitter conclusion for now.

The authors of two papers published by the journal Nature, which claimed to have produced embryonic-like stem cells from adult cells, have retracted them.

The papers said that almost any adult cell could be coaxed into becoming a stem cell just by dipping them in a bath of acid for 30 minutes. The method held great promise for regenerative medicine because it could be used to create any cell without needing to reprogram genes, or destroy an embryo. The team, led by researchers at the Riken Institute in Kobe, Japan, called this technique stimulustriggered acquisition of pluripotency, or STAP.

But in the months after publication, no independent team was able to replicate the experiments. Instead, the researchers around the world scrutinising the papers exposed many flaws in the papers including manipulated pictures of protein gel panels and mislabelled images. A public flogging of many high profile researchers ensued (see ""How the STAP cell story unfolded", below) and Nature's review process was thrust into the spotlight.

The journal published two statements today from the authors saying they were retracting both papers. The statements include an apology from the authors, in which they admit that multiple errors impair the credibility of the study. They concede that they are unable to say without doubt whether the STAP cell phenomenon is real.

An accompanying Nature editorial says that in practice, it may be impossible for journals to police gel panels routinely "without disproportionate editorial effort". The journal says it is now reviewing its screening practices to increase such checks.

The editorial goes on to say that Nature believes that its editors and referees could not have detected the fatal faults in this work. However, it emerged during the investigation that the papers were first submitted for publication in Science. According to a Nature News blog, Science rejected them after spotting the manipulated images and warning the lead author of the papers, Haruko Obokata, that such composite images need to be marked. Soon after the papers were published, independent bloggers started finding discrepancies in the work.

The Nature editorial states that the episode has highlighted flaws in Nature's procedures. The journal says that it needs to put quality assurance even higher on its agenda to make sure that people's trust in science is not betrayed.

Charles Vacanti at Harvard Medical School, one of the authors on the papers, has said that he is deeply saddened by the whole episode, although he continues to believe that none of the issues cast doubt on the existence of STAP cells themselves. He says he is encouraged that Riken president Ryoji Noyori and other independent labs will now allow sufficient time to try to replicate the experiments.

29 January Two high profile papers are published in Nature claiming that adult cells could be coaxed into becoming stem cells by dipping them in a bath of acid for 30 minutes. The team call these new cells stimulustriggered acquisition of stem cells, or STAP cells.

Read this article:
Acid-bath stem cell papers are finally retracted

Stem cells: Hope on the line

By adminJuly 2, 2014Uncategorized

On a brilliant day in April, tens of thousands of baseball fans stream past Jonathan Thomas's office towards AT&T Park for the first home game of the San Francisco Giants 2014 season. Thomas's standing desk faces away from the window, but the cheering throngs are never far from his mind.

Thomas chairs the board of the California Institute for Regenerative Medicine (CIRM), the US$3-billion agency hailed by scientists around the world for setting a benchmark for stem-cell research funding. But scientists will not be the ones who decide what becomes of CIRM when the cash runs out in 2017. Instead, it will be the orange-and-black-clad masses walking past Thomas's window. And to win their support, Thomas knows that the agency needs to prove that their collective investment has been worthwhile. We need to drive as many projects to the patient as soon as possible, he says.

Californians voted CIRM into existence in 2004, making it the largest funder of stem-cell work in the world. The money the proceeds of bond sales that must be repaid with $3 billion in interest by taxpayers helped to bring 130 scientists to the state, and created several thousand jobs there. It has funded research that led to the publication of more than 1,700 papers, and it has contributed to five early clinical trials.

The institute has navigated a difficult path, however. CIRM had to revamp its structure and practices in response to complaints about inefficiency and potential conflicts of interest. It has also had to adapt its mission to seismic shifts in stem-cell science.

Now, ten years after taking off, the agency is fighting for its future. It has a new president, businessman Randal Mills, who replaces biologist Alan Trounson. Its backers have begun to chart a course for once again reaching out to voters, this time for $5 billion (with another $5 billion in interest) in 2016. And it is under intense pressure to produce results that truly matter to the public.

Whether or not CIRM succeeds, it will serve as a test bed for innovative approaches to funding. It could be a model for moving technologies to patients when conventional funding sources are not interested.

Much of what is celebrated and lamented about CIRM can be traced back to the Palo Alto real-estate developer who conceived of it: Robert Klein. Although officially retired from CIRM he chaired the board from 2004 to 2011 (see 'State of funding') Klein's office is adorned with mementos of the agency: a commemorative shovel from the groundbreaking of a CIRM-funded stem-cell research centre, and a photo of him with former governor Arnold Schwarzenegger at the ribbon-cutting ceremony.

Liz Hafalia/San Francisco Chronicle/Polaris/eyevine

Patient advocates and parents at a 2012 meeting in which US$100 million in CIRM grants were approved.

It was Klein's idea to ask voters to support stem-cell research in 2004, through a ballot measure called Proposition 71. When he succeeded, CIRM instilled a kind of euphoria in stem-cell scientists, who were at the time still reeling from a 2001 decree by then-President George W. Bush that severely limited federal funding for embryonic-stem-cell research. California's commitment removed this roadblock and revealed that many in the state and the country supported the research.

Excerpt from:
Stem cells: Hope on the line

News Review From Harvard Medical School — Transplant May Help Adults with Sickle Cell

By adminJuly 2, 2014Stem Cell Treatment

July 2, 2014

News Review From Harvard Medical School -- Transplant May Help Adults with Sickle Cell

A partial transplant of bone-marrow stem cells may reverse sickle cell disease in adults, a new study finds. People with sickle cell disease have abnormally shaped red blood cells. They get stuck in blood vessels. This causes organ damage, pain and other medical problems. The new study included 30 adults with severe sickle cell disease. Each of them had a brother or sister who was a suitable match for a bone-marrow stem cell transplant. The sibling donor's cells were mixed with some of the patient's own cells. During 3.4 years of follow-up, the partial transplant reversed sickle cell disease in 26 out of 30 people, researchers said. In these patients, the bone marrow began making normal red blood cells. Fifteen people also were able to stop taking drugs to prevent rejection of the transplant. Overall, people were much less likely than before to need hospital treatment for the disease. Use of narcotic drugs for pain also was greatly reduced. The Journal of the American Medical Association published the study. HealthDay News wrote about it July 1.

By Howard LeWine, M.D.Harvard Medical School

What Is the Doctor's Reaction?

In the United States, more than 90,000 people are affected by sickle cell disease. Most of them are African-American. Worldwide, the number is much higher. About 300,000 babies are born with this genetic disease every year.

In sickle cell disease, the red blood cells made in the bone marrow are abnormal. Instead of having a normal round shape, the cells are curved and stiff. This causes the red blood cells to get stuck inside blood vessels before they reach the tissues. The result:

Marrow transplants can reverse adult sickle cell

By adminJuly 2, 2014Stem Cell Treatment

CHICAGO (AP) Bone marrow transplants can reverse severe sickle cell disease in adults, a small study by government scientists found, echoing results seen with a similar technique used in children.

The researchers and others say the findings show age need not be a barrier and that the technique may change practice for some adult patients when standard treatment fails.

The transplant worked in 26 of 30 adults, and 15 of them were even able to stop taking drugs that prevent rejection one year later.

"We're very pleased," said Dr. John Tisdale, the study's senior author and a senior investigator at the National Institutes of Health. "This is what we hoped for."

The treatment is a modified version of bone marrow transplants that have worked in kids. Donors are a brother or sister whose stem cell-rich bone marrow is a good match for the patient.

Tisdale said doctors have avoided trying standard transplants in adults with severe sickle cell disease because the treatment is so toxic. Children can often tolerate it because the disease typically hasn't taken as big a toll on their bodies, he said.

The disease is debilitating and often life-shortening; patients die on average in their 40s, Tisdale said. That's one reason why the researchers decided to try the transplants in adults, with hopes that the technique could extend their lives.

The treatment involves using chemotherapy and radiation to destroy bone marrow before replacing it with healthy donor marrow cells. In children, bone marrow is completely wiped out. In the adult study, the researchers only partially destroyed the bone marrow, requiring less donor marrow. That marrow's healthy blood cells outlast sickle cells and eventually replace them.

Sickle cell disease is a genetic condition that damages oxygen-carrying hemoglobin in red blood cells, causing them to form abnormal, sickle shapes that can block blood flow through the veins. It can cause anemia, pain and organ damage. The disease affects about 100,000 Americans, mostly blacks, and millions worldwide.

Results from the adult study, involving patients aged 29 on average, were published Tuesday in the Journal of the American Medical Association. The usual treatment hadn't worked, a drug called hydroxyurea, and they had transplants at an NIH research hospital in Bethesda, Maryland.

Read this article:
Marrow transplants can reverse adult sickle cell

UVA Expands Cancer Treatment

By adminJuly 1, 2014Stem Cell Medical Center

UVA joins National Marrow Donor Program giving greater access to cancer treatments by Ishaan Sachdeva | Jun 25 2014 | 06/25/14 10:11pm | Updated 19 hours ago

The Emily Couric Cancer Center of the University of Virginia Health System has expanded its access to bone marrow and hematopoietic stem cell transplant donors. Now designated as a National Marrow Donor Program (NMDP), the Health System will have access to the Be The Match Registry, the worlds largest and most diverse bone marrow registry. Implications of this change are significant for patients afflicted with blood cancers like leukemia who obtain treatment through the Health System.

Bone marrow, the soft, spongy tissue within bones like the sternum or the ilium of the pelvis, forms hematopoietic or blood-forming stem cells. These cells, unlike embryonic stem cells, differentiate only into types of blood cells- red blood cells, white blood cells or clotting platelets. Leukemia causes bone marrow to produce abnormal, leukemic white blood cells that divide uncontrollably, forming tumors that deprive cells of oxygen and reduce infection defense. One treatment method is autologous bone marrow transplant, in which patients receive stem cells from their healthy, non cancerous bone marrow.

The idea [of autologous transplants] is that you extract healthier bone marrow from the patient to have a source of stored, non-cancerous bone marrow. You can then treat the patient with higher doses of treatment than you can normally give because the most common limitation to treatment is that treatment will kill off healthy bone marrow you might have, said Thomas P. Loughran Jr., MD, the Universitys Cancer Center director.

Essentially, a patients healthy bone marrow is safeguarded outside their body while aggressive treatment is administered to kill cancerous marrow. Another form of treatment is allogeneic treatment, in which bone marrow is transplanted from a sibling or an unrelated donor.

In an allogeneic transplant, you are also transplanting in a new immune system. The new immune system comes in and recognizes the body as a foreign tissue and starts attacking that tissue. This causes a beneficial graft vs. leukemia effect where this new immune system attacks any residual leukemia, but may also cause a harmful graft versus host disease where normal tissue is also attacked, Loughran said.

The donor and recipient tissue interaction underscores the genetic component of bone marrow transplants from external donors. Despite the curative potential of a bone marrow transplant, a strong genetic match between donor and recipient is crucial to the utility of a transplant.

The ability of any donor to be successful is based on genetics. Its called HLA [human leukocyte antigen] typing. The HLA system has four genes called A, B, C and D, and it turns out that A, B and D are influential. We have half of our genes each from both parents, so we have six of these: 2 A, 2 B and 2 D. The best case is a six out of six match from a brother or sister, but the chances are only 1 in 4, said Loughran. The consequence of low genetic probabilities is a large pool of unrelated donors, like the Be The Match Registry. Through such services, patients have a greater chance of finding an unrelated donor who may provide a successful genetic match.

The coordinating center would identify the place where the donor is living and tell them they are potentially able to donate. In the past, the donor would have bone marrow directly extracted. Now it is almost always from the PBSCT [peripheral blood stem cell transplantation] procedure. The donor takes a growth factor that stimulates growth of the needed hematopoietic stem cells within their peripheral blood circulation. A catheter collects this blood and the stem cells are separated from the blood by a machine, and the blood is returned back to the donor. The collected stem cells are sent to the lab where they are purified and frozen, Loughran said.

Meanwhile, the patient in preparation for the transplant is given the highest dose of chemotherapy that can be tolerated. The donated stem cells are administered to the patient in a way similar to IV fluid.

Read the original here:
UVA Expands Cancer Treatment

New method to grow zebrafish embryonic stem cells

By adminJuly 1, 2014Stem Cell Clinic

Date:

June 30, 2014

Source:

Mary Ann Liebert, Inc., Publishers

Summary:

Zebrafish, a model organism that plays an important role in biological research and the discovery and development of new drugs and cell-based therapies, can form embryonic stem cells (ESCs). For the first time, researchers report the ability to maintain zebrafish-derived ESCs for more than two years without the need to grow them on a feeder cell layer.

Ho Sing Yee and coauthors from the Malaysian Ministry of Science, Technology and Innovation (Pulau Pinang), Universiti Sains Malaysia (Penang), and National University of Singapore describe the approach they used to be able to maintain zebrafish stem cells in culture and in an undifferentiated state for long periods of time. The ability to establish and grow the zebrafish ESCs without having a feeder layer of cells to support them simplifies their use and could expand their utility. In the article "Derivation and Long-Term Culture of an Embryonic Stem Cell-Like Line from Zebrafish Blastomeres Under Feeder-Free Condition," the authors show that the ESCs retain the morphology, properties, and ability to differentiate into a variety of cell types that is characteristic of ESCs, and were used to generate offspring after transmission through the germline.

"By addressing a major technical bottleneck in the field, this new culture system enables an array of exciting cellular and molecular genetic manipulations for the zebrafish," says Stephen Ekker, PhD, Editor-in-Chief of Zebrafish and Professor of Medicine at Mayo Clinic, Rochester, MN.

Story Source:

The rest is here:
New method to grow zebrafish embryonic stem cells

Global Stem Cells Group Subsidiary Regenestem Announces Grand Opening of State-of-the-Art Regenestem Asia Stem Cell …

By adminJuly 1, 2014Uncategorized

Miami (PRWEB) July 01, 2014

Global Stem Cells Group announced the grand opening of Regenestem Asia in Manila, Philippines, adding a new state-of-the-art clinic to the international stem cell medicine company's growing worldwide presence. With clinics in Miami, New York, Los Angeles and Dubai, Regenestem Asia now offers the same comprehensive stem cell treatments and experienced medical staff that have fueled the company's worldwide growth.

The launch of Regenestem Asia is a collaborative effort between Global Stem Cells Group and Eric Yalung, M.D. of the Cosmetic Surgery Institute-Manila, Inc., a prominent plastic surgeon committed to taking stem cell medicine, research and practice in the Philippines to a world-class level. The first Regenestem brand clinic in the Philippines, Regenestem Asia is a 22,000 square foot facility with a focus on offering the most advanced protocols in cosmetic cellular medicine to patients from around the world.

Under Yalung's leadership as Regenestem Medical Director, patients will receive the latest and least-invasive techniques in Stem Cell medicine available. Yalung is joined by a team of talented stem cell specialists to provide world-class patient treatment and follow-up care under the Regenestem brand.

In addition to cosmetic treatments, Regenestem offers stem cell treatments for arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes and multiple sclerosis among many other medical conditions at various facilities worldwide.

As part of its commitment to maintaining the highest standards in service and technology, Regenestem Asia provides an international staff experienced in administering the leading cellular therapies available.

Like all Regenestem facilities, Regenestem Asia is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

For more information, visit the Regenestem website, email bnovas(at)regenestem(dot)com or call 305-224-1858.

About Regenestem:

Regenestem is a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialists-professionals trained in the latest cutting-edge techniques in cellular medicine-Regenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.

Read the original here:
Global Stem Cells Group Subsidiary Regenestem Announces Grand Opening of State-of-the-Art Regenestem Asia Stem Cell ...

Research team pursues techniques to improve elusive stem cell therapy

By adminJuly 1, 2014Uncategorized

Stem cell scientists had what first appeared to be an easy win for regenerative medicine when they discovered mesenchymal stem cells several decades ago. These cells, found in the bone marrow, can give rise to bone, fat, and muscle tissue, and have been used in hundreds of clinical trials for tissue repair. Unfortunately, the results of these trials have been underwhelming. One problem is that these stem cells don't stick around in the body long enough to benefit the patient.

But Harvard Stem Cell Institute (HSCI) scientists at Boston Children's Hospital aren't ready to give up. A research team led by Juan Melero-Martin, PhD, recently found that transplanting mesenchymal stem cells along with blood vessel-forming cells naturally found in circulation improves results. This co-transplantation keeps the mesenchymal stem cells alive longer in mice after engraftment, up to a few weeks compared to hours without co-transplantation. This improved survival gives the mesenchymal stem cells sufficient time to display their full regenerative potential, generating new bone or fat tissue in the recipient mouse body. The finding was published in the Proceedings of the National Academy of Sciences (PNAS).

"We are losing mesenchymal stem cells very rapidly when we transplant them into the body, in part, because we are not giving them what they need," said Melero-Martin, an HSCI affiliated faculty member and an assistant professor of surgery at Boston Children's Hospital, Harvard Medical School.

"In the body, these cells sit very close to the capillaries, constantly receiving signals from them, and even though this communication is broken when we isolate mesenchymal stem cells in a laboratory dish, they seem to be ok because we have learned how to feed them," he said. "But when you put the mesenchymal stem cells back into the body, there is a period of time when they will not have this proximity to capillary cells and they start to die; so including these blood vessel-forming cells from the very beginning of a transplantation made a major difference."

Melero-Martin's research has immediate translational implications, as current mesenchymal clinical trials don't follow a co-transplantation procedure. He is already collaborating with surgical colleagues at Boston Children's Hospital to see if his discovery can help improve fat and bone grafts. However, giving patients two different types of cells, as opposed to just one, would require more time and experiments to determine safety and efficacy. Melero-Martin is seeking to identify the specific signals mesenchymal stem cells receive from the blood vessel-forming cells in order to be able to mimic the signals without the cells themselves.

"Even though mesenchymal stem cells have been around for a while, I think there is still a lack of fundamental knowledge about communication between them and other cells in the body," he said. "My lab is interested in going even beyond what we found to try to understand whether these cell-cell signals are different in each tissue of the body, and to learn how to educate both blood vessel-forming and mesenchymal stem cells to co-ordinate tissue specific regenerative responses."

Other Harvard Stem Cell Institute researchers are studying mesenchymal stem cells as bioengineering tools to deliver therapeutics, which is possible because of the cell type's unique ability to not trigger an immune response. Jeffrey Karp, PhD, at Brigham and Women's Hospital has developed several methods to turn these cells into drug-delivery vehicles, so that after transplantation they can, for example, hone in on swollen tissue and secrete anti-inflammatory compounds. And Khalid Shah, PhD, at Massachusetts General Hospital has designed a gel that holds mesenchymal stem cells in place so that they can expose brain tumors to cancer-killing herpes viruses.

"A lot of these applications have no real direct link with mesenchymal stem cells' supposed progenitor cell function," Melero-Martin said. "In our study, we went back to the collective ambition to use these cells as a way to regenerate tissues and we are not in a position to say how that affects other uses that people are proposing."

Story Source:

The above story is based on materials provided by Harvard University. Note: Materials may be edited for content and length.

More:
Research team pursues techniques to improve elusive stem cell therapy

Studies Test Effectiveness and Safety of Stem Cell Treatment for Urinary Incontinence

By adminJuly 1, 2014Stem Cell Treatment

Durham, NC (PRWEB) July 01, 2014

Medication and minimally invasive surgery to implant a sling can provide relief for millions of people who suffer from stress urinary incontinence (SUI), but not everyone responds to these therapeutic methods. A new study in the current STEM CELLS Translational Medicine tests the safety and effectiveness of stem cells as an alternative SUI treatment.

SUI results when the pelvic floor muscles, which support the bladder and urethra, weaken to the point that the muscles are not able to prevent urine from flowing when pressure is placed on the abdomen, such as when the person laughs or coughs. It occurs most often in women, due to childbirth and pregnancy.

Tissue engineering offers an attractive method to regenerate sphincter muscle, explained the studys corresponding author, Kirsi Kuismanen, from the department of obstetrics and gynecology at Tampere University Hospital (TUH) in Finland. She and her TUH colleagues teamed up with researchers from the Adult Stem Cell Group of BioMediTech in Tampere and the University of Twente in the Netherlands on the study.

Previously, various different cell sources, such as skeletal muscle-derived stem cells (SkMSCs), mesenchymal stem cells derived from bone marrow (BMSCs) and adipose stem cells (ASCs), have been studied for treating urinary incontinence. The SkMSCs and BMSCs would be a potential alternative for incontinence therapy. However, when compared to ASCs, the major limitation of SkMSCs and BMSCs is the difficulty to obtain these cells in large quantities, Dr. Kuismanen said.

The study involved five SUI patients who either did not want a sling implant or had undergone implants but they proved unsuccessful. They were treated with ASCs combined with bovine collagen gel, which is a bulking agent, and saline.

Prior to the treatment, the ASCs were isolated from subcutaneous fat and expanded for three weeks in a laboratory. The mixture of ASCs and collagen was injected in the patients who were followed for three, six and 12 months after the injections. The primary end point was a cough test to measure the effect of the treatment. Validated questionnaires were used to determine the subjective cure rate.

After six months, one out of five patients displayed a negative cough test with full bladder. At one year, the cough test was negative with three patients; two were satisfied with the results and ended their treatment for SUI. Validated questionnaires showed some subjective improvement in all five patients.

This is the first study describing the use of autologous ASCs in combination with collagen gel for female SUI treatments, Dr. Kuismanen said. Thus far, the treatment with autologous ASCs has proven safe and well tolerated. However, the feasibility and efficacy of the treatment were not optimal so additional research is needed to develop SUI injection therapies.

New treatments are needed for this common condition that affects millions of women, said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. The current study, believed to be the first to evaluate adipose-derived stem cells in combination with collagen, adds to the body of knowledge about the safety and effectiveness of stem cell treatments for stress urinary incontinence.

See the rest here:
Studies Test Effectiveness and Safety of Stem Cell Treatment for Urinary Incontinence